Though the subcutaneous model is adequate to provide insight into pharmacokinetics and targeting properties of the DTPA-700DX-MB, we do believe that further studies into the biological effects of the FAP-targeted PDT should be investigated in orthotopic models because those better reflect the local environment in which the tumours develop. The gene discussed is FAP; the disease is neoplasm.